Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib

New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.

Detalles Bibliográficos
Autores principales: Alshiekh‐Nasany, Ruham, Zidan, Awss, Martinez, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134215/
https://www.ncbi.nlm.nih.gov/pubmed/27980759
http://dx.doi.org/10.1002/ccr3.729
_version_ 1782471423314362368
author Alshiekh‐Nasany, Ruham
Zidan, Awss
Martinez, Carmen
author_facet Alshiekh‐Nasany, Ruham
Zidan, Awss
Martinez, Carmen
author_sort Alshiekh‐Nasany, Ruham
collection PubMed
description New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality.
format Online
Article
Text
id pubmed-5134215
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51342152016-12-15 Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib Alshiekh‐Nasany, Ruham Zidan, Awss Martinez, Carmen Clin Case Rep Case Reports New‐generation tyrosine kinase inhibitors (TKI) are promising agents for the treatment of chronic myeloid leukemia (CML), but the linkage to vascular diseases warrants a special attention from treating physicians, as it may carry major morbidity and mortality. John Wiley and Sons Inc. 2016-11-09 /pmc/articles/PMC5134215/ /pubmed/27980759 http://dx.doi.org/10.1002/ccr3.729 Text en © 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Alshiekh‐Nasany, Ruham
Zidan, Awss
Martinez, Carmen
Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
title Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
title_full Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
title_fullStr Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
title_full_unstemmed Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
title_short Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
title_sort extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor nilotinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134215/
https://www.ncbi.nlm.nih.gov/pubmed/27980759
http://dx.doi.org/10.1002/ccr3.729
work_keys_str_mv AT alshiekhnasanyruham extensiveintracranialarterialstenosesinconjunctionwiththeuseoftyrosinekinaseinhibitornilotinib
AT zidanawss extensiveintracranialarterialstenosesinconjunctionwiththeuseoftyrosinekinaseinhibitornilotinib
AT martinezcarmen extensiveintracranialarterialstenosesinconjunctionwiththeuseoftyrosinekinaseinhibitornilotinib

Ejemplares similares